JULY 17, 2024
Orexo Q2 2024 Interim Report
News & Insights
JULY 16, 2024
Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose
JULY 10, 2024
Orexo AB´s sustainability work ranked among top 5% by EcoVadis
A commercial stage pharmaceutical company with three revenue generating pharmaceutical products
AmorphOX® - a world-class powder-based drug delivery technology, leading to a new wave of a both small and large molecule pharmaceuticals.
Development pipeline targeting large medical needs
ESG sustainable investing
Read all documents related to the refinancing of the existing bond - MARCH 2024
Key financial figures
Group net revenue
615 MSEK
Last Twelve Months, Q323-Q224
Group EBITDA
24 MSEK
Last Twelve Months, Q323-Q224
US Commercial segment EBIT
145 MSEK
Last Twelve Months, Q323-Q224
Cash position
140 MSEK
Q224